AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Molecular subtype-guided precision medicine now enables individualized systemic therapy for EBC via novel agents and biomarker-driven strategies, optimizing clinical decisions and improving outcomes.
Current treatment strategies across breast cancer subtypes are summarized, emerging therapies are highlighted, and the expanding APP role is emphasized.
Advances in targeted and immune-based therapies are transforming breast cancer care and Leveraging molecular insights, particularly for TNBC, is crucial to delivering personalised, clinically meaningful treatments and improving outcomes across all subtypes.
This review highlights advancements in immunotherapy strategies for mitigating TNBC, with a particular focus on targeting immunosuppressive molecules.
Key approaches targeting DNA repair deficiency, immune regulation, oncogenic signaling pathways, and antigen-directed therapies are highlighted, and their clinical development and application are discussed.
This framework integrates evidence level, disease stage, biomarker reliability and patient tolerance into treatment selection for TNBC precision therapy and distinguish them from maturing or exploratory strategies such as pathway-directed therapy, epigenetic modulation, anti-vascular combinations, regulated cell-death...
BACKGROUND Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth factor receptor 2 (HER2)-positive disease. More recently, antibody-drug conjugates (ADCs), established...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.